Ben Blanc 26:25 And thats it for us
If your genetic variants affect GLP-1 receptor expression, sensitivity, or downstream signaling, the medication may never reach full therapeutic potential regardless of dose escalation
For example, dopamine receptor D2 (DRD2) polymorphisms are implicated in schizophrenia, where certain alleles may cause increased receptor sensitivity or density in certain brain regions, leading to dopamine dysregulation
There is strong research interest in the application of ipamorelin to improve athletic performance but no research currently exists to show how it may be dosed for this purpose [14]
A separate survey of 105 large employers by the Business Group on Health found that while two-thirds currently cover GLP-1s for weight management, 10% plan to drop that coverage in 2027 and only 72% are committed to continuing it
That creates a dangerous mismatch